ip eline drugs in the Primary Progressive Multiple Sclerosis pipeline landscapes. It comprises PPMS pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Primary Progressive Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive PPMS pipeline products. Some of the crucial features of the Primary Progressive Multiple Sclerosis key players such as Atara Biotherapeutics, MediciNova, AB Science, and many others involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Different therapeutic candidates are segmented into early-stage, mid-stage, and late-stage of development for the PPMS treatment.